# reload+after+2024-01-22 16:46:24.140188
address1§24 Crosby Drive
city§Bedford
state§MA
zip§01730
country§United States
phone§781 357 4000
fax§781 357 4001
website§https://www.ocutx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
fullTimeEmployees§274
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Antony  Mattessich', 'age': 55, 'title': 'President, CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1049350, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Donald  Notman Jr.', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'totalPay': 630872, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rabia Gurses Ozden M.D.', 'age': 55, 'title': 'Chief Medical Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 621386, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peter K. Jarrett Ph.D.', 'age': 66, 'title': 'Chief Scientific Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Philip C. Strassburger Esq.', 'age': 63, 'title': 'General Counsel', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 282613, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William H. Ransone II', 'title': 'Vice President of Global Sales & Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracy  Smith', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher G. White', 'age': 61, 'title': 'Chief Business Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karen-Leigh  Edwards M.B.A., Ph.D.', 'title': 'Senior Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steve  Meyers', 'title': 'Senior Vice President of Commercial', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§10
shareHolderRightsRisk§7
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.023
priceToSalesTrailing12Months§8.754641
currency§USD
dateShortInterest§1702598400
forwardEps§-1.0
exchange§NGM
quoteType§EQUITY
shortName§Ocular Therapeutix, Inc.
longName§Ocular Therapeutix, Inc.
firstTradeDateEpochUtc§1406295000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e
gmtOffSetMilliseconds§-18000000
targetHighPrice§35.0
targetLowPrice§8.0
targetMeanPrice§15.33
targetMedianPrice§11.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§3.825
grossMargins§-0.09689999
ebitdaMargins§-1.37181
trailingPegRatio§None
